Abstract:A non-coding region on chromosome 9p21 was previously shown to associate with coronary artery disease and type 2 diabetes, and the region has been implicated in regulating neighbouring genes. Here the authors identify 33 distinct enhancers within this region and show that single nucleotide polymorphisms in one of the enhancers affect STAT1 binding. They further show that in human vascular endothelium cells, the enhancer interval physically interacts with a number of specific loci, and that interferon-γ activation strongly affects the chromatin structure and transcriptional regulation of the 9p21 locus, including STAT1 binding, long-range enhancer interactions and expression of neighbouring genes. A non-coding region on chromosome 9p21 was previously shown to associate with coronary artery disease and type 2 diabetes, and the region has been implicated in regulating neighbouring genes. Here, 33 distinct enhancers within this region are identified, showing that SNPs in one of the enhancers affect STAT1 binding. Furthermore, it is shown that in human vascular endothelial cells the enhancer interval physically interacts with a number of specific loci and that IFN-γ activation strongly affects the chromatin structure and transcriptional regulation of the 9p21 locus, including STAT1 binding, long-range enhancer interactions and expression of neighbouring genes. Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) in the 9p21 gene desert associated with coronary artery disease (CAD)1,2,3,4 and type 2 diabetes5,6,7. Despite evidence for a role of the associated interval in neighbouring gene regulation8,9,10, the biological underpinnings of these genetic associations with CAD or type 2 diabetes have not yet been explained. Here we identify 33 enhancers in 9p21; the interval is the second densest gene desert for predicted enhancers and six times denser than the whole genome (P < 6.55 × 10−33). The CAD risk alleles of SNPs rs10811656 and rs10757278 are located in one of these enhancers and disrupt a binding site for STAT1. Lymphoblastoid cell lines homozygous for the CAD risk haplotype show no binding of STAT1, and in lymphoblastoid cell lines homozygous for the CAD non-risk haplotype, binding of STAT1 inhibits CDKN2BAS (also known as CDKN2B-AS1) expression, which is reversed by short interfering RNA knockdown of STAT1. Using a new, open-ended approach to detect long-distance interactions, we find that in human vascular endothelial cells the enhancer interval containing the CAD locus physically interacts with the CDKN2A/B locus, the MTAP gene and an interval downstream of IFNA21. In human vascular endothelial cells, interferon-γ activation strongly affects the structure of the chromatin and the transcriptional regulation in the 9p21 locus, including STAT1-binding, long-range enhancer interactions and altered expression of neighbouring genes. Our findings establish a link between CAD genetic susceptibility and the response to inflammatory signalling in a vascular cell type and thus demonstrate the utility of genome-wide association study findings in directing studies to novel genomic loci and biological processes important for disease aetiology.

The 9p21.3 coronary artery disease risk locus drives vascular smooth muscle cells to an osteochondrogenic state

Abstract 2072: The 9p21.3 Coronary Artery Disease Risk Locus Induces Cell State Transitions In Vascular Smooth Muscle Cells

Unveiling the Role of the Most Impactful Cardiovascular Risk Locus through Haplotype Editing

P3.22 CHROMOSOME 9P21 LOCUS AND CORONARY ARTERY DISEASE – COLLABORATIVE META-ANALYSIS ON ANGIOGRAPHIC BURDEN AND MOLECULAR FUNCTION ANALYSIS

Comprehensive identification of coronary artery disease-associated variants regulating vascular smooth muscle cell gene expression

B: CHROMOSOME 9P21 LOCUS AND CORONARY ARTERY DISEASE – COLLABORATIVE META-ANALYSIS ON ANGIOGRAPHIC BURDEN AND MOLECULAR FUNCTION ANALYSIS

Genetic Regulation of Atherosclerosis-Relevant Phenotypes in Human Vascular Smooth Muscle Cells

Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells.

9P21 DNA Variants Associated with Coronary Artery Disease Impair Interferon-Γ Signalling Response

Coronary Artery Disease Genes SMAD3 and TCF21 Promote Opposing Interactive Genetic Programs That Regulate Smooth Muscle Cell Differentiation and Disease Risk.

Coronary Artery Disease Associated Transcription Factor TCF21 Regulates Smooth Muscle Precursor Cells That Contribute to the Fibrous Cap

Molecular Mechanisms of Coronary Disease Revealed Using Quantitative Trait Loci for TCF21 Binding, Chromatin Accessibility, and Chromosomal Looping

Micro-capture-C in vessel wall cell types identifies mechanisms underlying coronary artery disease susceptibility loci

Abstract 2077: the Epigenetic Regulator PRDM16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk

Epigenetic regulation at LRP1 risk locus for cardiovascular diseases and assessment of cellular function in hiPSC derived smooth muscle cells

Abstract 346: 9p21.3 Coronary Artery Disease Risk Variants Disrupt Tead Transcription Factor Binding and Tead-dependent Tgfβ Induction of P16 Expression

LRP1 Repression by SNAIL Results in ECM Remodeling in Genetic Risk for Vascular Diseases

Single cell variant to enhancer to gene map for coronary artery disease

Trans-interaction of risk loci 6p24.1 and 10q11.21 is associated with endothelial damage in coronary artery disease

126 CHROMOSOME 9P21 LOCUS AND ANGIOGRAPHIC CORONARY ARTERY DISEASE BURDEN: A COLLABORATIVE META-ANALYSIS

Abstract 218: Integration Of Coronary Artery Disease GWAS With Bulk And Single-cell Transcriptomics From Atherosclerotic Plaques By Deconvolution, Reveals Novel Smooth Muscle Cell Genes